Last reviewed · How we verify
Lipofundin N 20%
Lipofundin N 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.
Lipofundin N 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally. Used for Parenteral nutrition in patients unable to maintain adequate oral or enteral intake, Post-operative nutritional support, Critical illness requiring intravenous nutritional supplementation.
At a glance
| Generic name | Lipofundin N 20% |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Drug class | Lipid emulsion; parenteral nutrition component |
| Modality | Small molecule |
| Therapeutic area | Nutrition support; Critical care |
| Phase | FDA-approved |
Mechanism of action
This intravenous lipid emulsion contains soybean oil and medium-chain triglycerides, supplying both essential polyunsaturated fatty acids (linoleic and alpha-linolenic acid) and energy substrate. It is administered as part of total parenteral nutrition (TPN) regimens to maintain nutritional status, support immune function, and provide concentrated caloric support in critically ill, post-operative, or malnourished patients.
Approved indications
- Parenteral nutrition in patients unable to maintain adequate oral or enteral intake
- Post-operative nutritional support
- Critical illness requiring intravenous nutritional supplementation
Common side effects
- Hypertriglyceridemia
- Lipemia
- Infusion site reactions
- Hepatic steatosis (with prolonged use)
- Thrombophlebitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipofundin N 20% CI brief — competitive landscape report
- Lipofundin N 20% updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI